{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:57:18Z","timestamp":1790485038620,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54893-3","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:44:51Z","timestamp":1782675891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Searching for BBB permeable phytochemical inhibitors for targeting brain cancer associated HER2 protein through free energy calculations and pharmacokinetic analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Abhishek","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Arul","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"54893_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"54893_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/BF02893497","volume":"13","author":"AR Beser","year":"2007","unstructured":"Beser, A. R. et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol. Oncol. Res. POR 13, 180\u2013185 (2007).","journal-title":"Pathol. Oncol. Res. POR"},{"key":"54893_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/319226a0","volume":"319","author":"CI Bargmann","year":"1986","unstructured":"Bargmann, C. I., Hung, M.-C. & Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226\u2013230 (1986).","journal-title":"Nature"},{"key":"54893_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","volume":"125","author":"D Pasquier","year":"2020","unstructured":"Pasquier, D. et al. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur. J. Cancer 125, 22\u201330 (2020).","journal-title":"Eur. J. Cancer"},{"key":"54893_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/13543784.2025.2472411","volume":"34","author":"C Hoyek","year":"2025","unstructured":"Hoyek, C., Zheng-Lin, B., Jones, J. & Bekaii-Saab, T. Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects. Expert Opin. Investig. Drugs 34, 161\u2013168 (2025).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"54893_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.urology.2003.10.040","volume":"63","author":"CL Coogan","year":"2004","unstructured":"Coogan, C. L., Estrada, C. R., Kapur, S. & Bloom, K. J. HER-2\/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63, 786\u2013790 (2004).","journal-title":"Urology"},{"key":"54893_CR7","doi-asserted-by":"publisher","first-page":"175883592312250","DOI":"10.1177\/17588359231225037","volume":"16","author":"B Zheng-Lin","year":"2024","unstructured":"Zheng-Lin, B. & Bekaii-Saab, T. S. Treatment options for HER2-expressing colorectal cancer: updates and recent approvals. Ther. Adv. Med. Oncol. 16, 17588359231225036 (2024).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"54893_CR8","first-page":"4087","volume":"50","author":"A Berchuck","year":"1990","unstructured":"Berchuck, A. et al. Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50, 4087\u20134091 (1990).","journal-title":"Cancer Res."},{"key":"54893_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-018-0797-x","volume":"17","author":"R Butti","year":"2018","unstructured":"Butti, R. et al. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol. Cancer 17, 34 (2018).","journal-title":"Mol. Cancer"},{"key":"54893_CR10","doi-asserted-by":"publisher","first-page":"16779","DOI":"10.1007\/s00210-025-04297-3","volume":"398","author":"KS Prabhu","year":"2025","unstructured":"Prabhu, K. S. et al. PI3 K\/AKT\/mTOR pathway and its role in breast cancer stem cells. Naunyn. Schmiedebergs Arch. Pharmacol. 398, 16779\u201316795 (2025).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"54893_CR11","doi-asserted-by":"publisher","first-page":"E3119","DOI":"10.1073\/pnas.1216078109","volume":"109","author":"DP Kodack","year":"2012","unstructured":"Kodack, D. P. et al. Combined targeting of HER2 and VEGFR2 for effective treatment ofHER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. 109, E3119\u2013E3127 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"54893_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010051","volume":"15","author":"KS Vega Cano","year":"2022","unstructured":"Vega Cano, K. S., Marmolejo Casta\u00f1eda, D. H., Escriv\u00e1-de-Roman\u00ed, S. & Saura, C. Systemic therapy for HER2-positive metastatic breast cancer: current and future trends. Cancers 15, 51 (2022).","journal-title":"Cancers"},{"key":"54893_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122927","volume":"13","author":"A Garcia-Alvarez","year":"2021","unstructured":"Garcia-Alvarez, A., Papakonstantinou, A. & Oliveira, M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers 13, 2927 (2021).","journal-title":"Cancers"},{"key":"54893_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100256","volume":"6","author":"E Stavrou","year":"2021","unstructured":"Stavrou, E., Winer, E. P. & Lin, N. U. How we treat HER2-positive brain metastases. ESMO Open 6, 100256 (2021).","journal-title":"ESMO Open"},{"key":"54893_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","volume":"4","author":"J Wang","year":"2019","unstructured":"Wang, J. & Xu, B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct. Target. Ther. 4, 34 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"54893_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41523-023-00587-2","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer 9, 94 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"54893_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1007\/s12672-025-02792-w","volume":"16","author":"C Yalaza","year":"2025","unstructured":"Yalaza, C. et al. Identification of novel HER2 \u0131nhibitors: potential therapeutics for breast cancer. Discov. Oncol. 16, 1122 (2025).","journal-title":"Discov. Oncol."},{"key":"54893_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8304","author":"B Israel","year":"2018","unstructured":"Israel, B., Tilghman, S., Parker-Lemieux, K. & Payton-Stewart, F. Phytochemicals: current strategies for treating breast cancer (Review). Oncol. Lett. https:\/\/doi.org\/10.3892\/ol.2018.8304 (2018).","journal-title":"Oncol. Lett."},{"key":"54893_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.639628","volume":"12","author":"MdA Rahman","year":"2021","unstructured":"Rahman, Md. A. et al. Phytochemicals as a complement to cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway. Front. Pharmacol. 12, 639628 (2021).","journal-title":"Front. Pharmacol."},{"key":"54893_CR20","doi-asserted-by":"publisher","unstructured":"Sharma, D. K. & Hall, I. H. Hypolipidemic, Anti-Inflammatory, and Antineoplastic Activity and Cytotoxicity of Flavonolignans Isolated from Hydnocarpus wightiana Seeds. ACS Publications https:\/\/pubs.acs.org\/doi\/pdf\/https:\/\/doi.org\/10.1021\/np50077a010. (2004)","DOI":"10.1021\/np50077a010"},{"key":"54893_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/cimb47030193","volume":"47","author":"EJ Millan-Casarrubias","year":"2025","unstructured":"Millan-Casarrubias, E. J. et al. Molecular docking and pharmacological in silico evaluation of camptothecin and related ligands as promising HER2-Targeted therapies for breast cancer. Curr. Issues Mol. Biol. 47, 193 (2025).","journal-title":"Curr. Issues Mol. Biol."},{"key":"54893_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541\u2013553 (2005).","journal-title":"NeuroRx"},{"key":"54893_CR23","doi-asserted-by":"publisher","first-page":"D1124","DOI":"10.1093\/nar\/gks1047","volume":"41","author":"M Mangal","year":"2013","unstructured":"Mangal, M., Sagar, P., Singh, H., Raghava, G. P. S. & Agarwal, S. M. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 41, D1124\u2013D1129 (2013).","journal-title":"Nucleic Acids Res."},{"key":"54893_CR24","doi-asserted-by":"publisher","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","volume":"286","author":"K Aertgeerts","year":"2011","unstructured":"Aertgeerts, K. et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J. Biol. Chem. 286, 18756\u201318765 (2011).","journal-title":"J. Biol. Chem."},{"key":"54893_CR25","doi-asserted-by":"publisher","first-page":"8827","DOI":"10.1021\/acsomega.3c00156","volume":"8","author":"RP Vivek-Ananth","year":"2023","unstructured":"Vivek-Ananth, R. P., Mohanraj, K., Sahoo, A. K. & Samal, A. IMPPAT 2.0: an enhanced and expanded phytochemical atlas of indian medicinal plants. ACS Omega 8, 8827\u20138845 (2023).","journal-title":"ACS Omega"},{"key":"54893_CR26","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"54893_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-2105-15-261","volume":"15","author":"W Yim-im","year":"2014","unstructured":"Yim-im, W. et al. Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinformatics 15, 261 (2014).","journal-title":"BMC Bioinformatics"},{"key":"54893_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12010-021-03791-7","volume":"194","author":"LE Mendie","year":"2022","unstructured":"Mendie, L. E. & Hemalatha, S. Molecular Docking of Phytochemicals Targeting GFRs as Therapeutic Sites for Cancer: an In Silico Study. Appl. Biochem. Biotechnol. 194, 215\u2013231 (2022).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"54893_CR29","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1080\/07391102.2021.1891136","volume":"40","author":"SK Das","year":"2022","unstructured":"Das, S. K. et al. In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes. J. Biomol. Struct. Dyn. 40, 6857\u20136867 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"54893_CR30","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1080\/07391102.2021.1877823","volume":"40","author":"GS Purawarga Matada","year":"2022","unstructured":"Purawarga Matada, G. S. et al. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer. J. Biomol. Struct. Dyn. 40, 6183\u20136192 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"54893_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/07391102.2021.2014972","volume":"41","author":"S Lamichhane","year":"2023","unstructured":"Lamichhane, S. et al. Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach. J. Biomol. Struct. Dyn. 41, 897\u2013911 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"54893_CR32","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s11030-022-10573-8","volume":"27","author":"AKMH Morshed","year":"2023","unstructured":"Morshed, A. K. M. H. et al. Oncoinformatic screening of the gene clusters involved in the HER2-positive breast cancer formation along with the in silico pharmacodynamic profiling of selective long-chain omega-3 fatty acids as the metastatic antagonists. Mol. Divers. 27, 2651\u20132672 (2023).","journal-title":"Mol. Divers."},{"key":"54893_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3390\/ijms17071055","volume":"17","author":"J Li","year":"2016","unstructured":"Li, J., Wang, H., Li, J., Bao, J. & Wu, C. Discovery of a potential HER2 inhibitor from natural products for the treatment of HER2-positive breast cancer. Int. J. Mol. Sci. 17, 1055 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"54893_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/molecules22020308","volume":"22","author":"M Olivero-Acosta","year":"2017","unstructured":"Olivero-Acosta, M., Maldonado-Rojas, W. & Olivero-Verbel, J. Natural products as chemopreventive agents by potential inhibition of the kinase domain in ErbB receptors. Molecules 22, 308 (2017).","journal-title":"Molecules"},{"key":"54893_CR35","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.3390\/nu17132202","volume":"17","author":"W Justy\u0144ska","year":"2025","unstructured":"Justy\u0144ska, W. et al. Dietary polyphenols: luteolin, quercetin, and apigenin as potential therapeutic agents in the treatment of gliomas. Nutrients 17, 2202 (2025).","journal-title":"Nutrients"},{"key":"54893_CR36","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/cancers13102317","volume":"13","author":"K Zhai","year":"2021","unstructured":"Zhai, K. et al. Natural compounds in glioblastoma therapy: preclinical insights, mechanistic pathways, and outlook. Cancers 13, 2317 (2021).","journal-title":"Cancers"},{"issue":"9","key":"54893_CR37","doi-asserted-by":"publisher","first-page":"104115","DOI":"10.1016\/j.drudis.2024.104115","volume":"29","author":"TA Rahaman","year":"2024","unstructured":"Rahaman, T. A. & Chaudhary, S. Targeting cancer using scaffold-hopping approaches: illuminating SAR to improve drug design. Drug Discov. Today 29(9), 104115 (2024).","journal-title":"Drug Discov. Today"},{"key":"54893_CR38","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1039\/D4MD00492B","volume":"15","author":"G Issabayeva","year":"2024","unstructured":"Issabayeva, G. et al. Discovery of selective LATS inhibitors via scaffold hopping: enhancing drug-likeness and kinase selectivity for potential applications in regenerative medicine. RSC Med. Chem. 15, 4080\u20134089 (2024).","journal-title":"RSC Med. Chem."},{"key":"54893_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open babel: an open chemical toolbox. J. Cheminformatics 3, 33 (2011).","journal-title":"J. Cheminformatics"},{"key":"54893_CR40","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings. J. Chem. Inf. Model. 61, 3891\u20133898 (2021).","journal-title":"J. Chem. Inf. Model."},{"key":"54893_CR41","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"54893_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"54893_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug Discov. Today Technol."},{"key":"54893_CR44","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","volume":"9","author":"S-F Zhou","year":"2008","unstructured":"Zhou, S.-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9, 310\u2013322 (2008).","journal-title":"Curr. Drug Metab."},{"key":"54893_CR45","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee, P., Kemmler, E., Dunkel, M. & Preissner, R. ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 52, W513\u2013W520 (2024).","journal-title":"Nucleic Acids Res."},{"key":"54893_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1\u20132","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1\u20132, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"54893_CR47","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/prot.21123","volume":"65","author":"V Hornak","year":"2006","unstructured":"Hornak, V. et al. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65, 712\u2013725 (2006).","journal-title":"Proteins"},{"key":"54893_CR48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157\u20131174 (2004).","journal-title":"J. Comput. Chem."},{"key":"54893_CR49","doi-asserted-by":"publisher","first-page":"btad350","DOI":"10.1093\/bioinformatics\/btad350","volume":"39","author":"L Kagami","year":"2023","unstructured":"Kagami, L., Wilter, A., Diaz, A. & Vranken, W. The ACPYPE web server for small-molecule MD topology generation. Bioinformatics 39, btad350 (2023).","journal-title":"Bioinformatics"},{"key":"54893_CR50","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Valiente, P. A. & Moreno, E. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281\u20136291 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"54893_CR51","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296\u2013W303 (2018).","journal-title":"Nucleic Acids Res."},{"key":"54893_CR52","doi-asserted-by":"publisher","first-page":"8792","DOI":"10.3390\/ijms25168792","volume":"25","author":"P Chihomvu","year":"2024","unstructured":"Chihomvu, P., Ganesan, A., Gibbons, S., Woollard, K. & Hayes, M. A. Phytochemicals in drug discovery\u2014a confluence of tradition and innovation. Int. J. Mol. Sci. 25, 8792 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"54893_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106957","volume":"142","author":"Z Hui","year":"2024","unstructured":"Hui, Z. et al. Discovery of plant-derived anti-tumor natural products: potential leads for anti-tumor drug discovery. Bioorganic Chem. 142, 106957 (2024).","journal-title":"Bioorganic Chem."},{"key":"54893_CR54","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/antiox14070846","volume":"14","author":"J-Y Kim","year":"2025","unstructured":"Kim, J.-Y. et al. Hydnocarpin, a natural flavonolignan, induces the ROS-mediated apoptosis of ovarian cancer cells and reprograms tumor-associated immune cells. Antioxidants 14, 846 (2025).","journal-title":"Antioxidants"},{"key":"54893_CR55","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/15353702211004870","volume":"246","author":"S Lou","year":"2021","unstructured":"Lou, S. et al. Inhibitory effect of hydnocarpin D on T-cell acute lymphoblastic leukemia via induction of autophagy-dependent ferroptosis. Exp. Biol. Med. Maywood NJ 246, 1541\u20131553 (2021).","journal-title":"Exp. Biol. Med. Maywood NJ"},{"key":"54893_CR56","unstructured":"Petrikaite, V., K\u00e1\u0148ov\u00e1, K. & Valentov\u00e1, K. Activity of Flavonolignan Derivatives on Breast, Brain and Pancreatic Cancer Cell Lines. (2021)."},{"key":"54893_CR57","doi-asserted-by":"publisher","first-page":"153303382210809","DOI":"10.1177\/15330338221080974","volume":"21","author":"A Mehrabian","year":"2022","unstructured":"Mehrabian, A. et al. Nanocarriers call the last shot in the treatment of brain cancers. Technol. Cancer Res. Treat. 21, 15330338221080974 (2022).","journal-title":"Technol. Cancer Res. Treat."},{"key":"54893_CR58","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11033-024-09658-4","volume":"51","author":"S Zarei Shandiz","year":"2024","unstructured":"Zarei Shandiz, S., Erfani, B. & Hashemy, S. I. Protective effects of silymarin in glioblastoma cancer cells through redox system regulation. Mol. Biol. Rep. 51, 723 (2024).","journal-title":"Mol. Biol. Rep."},{"key":"54893_CR59","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/biom11121841","volume":"11","author":"K Zhai","year":"2021","unstructured":"Zhai, K., Mazurakova, A., Koklesova, L., Kubatka, P. & B\u00fcsselberg, D. Flavonoids synergistically enhance the anti-glioblastoma effects of chemotherapeutic drugs. Biomolecules 11, 1841 (2021).","journal-title":"Biomolecules"},{"key":"54893_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2022.105384","volume":"100","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Yuan, A.-J., Wu, Y.-J., Wu, L.-M. & Zhang, L. Silymarin in cancer therapy: mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations. J. Funct. Foods 100, 105384 (2023).","journal-title":"J. Funct. Foods"},{"key":"54893_CR61","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1038\/s41467-024-49748-2","volume":"15","author":"W Hou","year":"2024","unstructured":"Hou, W. et al. Divergent and gram-scale syntheses of (\u2013)-veratramine and (\u2013)-cyclopamine. Nat. Commun. 15, 5332 (2024).","journal-title":"Nat. Commun."},{"key":"54893_CR62","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1021\/jacs.4c16495","volume":"147","author":"MD Zott","year":"2025","unstructured":"Zott, M. D., Zuschlag, D. W. & Trauner, D. H. Concise synthesis of (-)-Veratramine and (-)-20-iso-Veratramine via aromative diels-alder reaction. J. Am. Chem. Soc. 147, 3010\u20133016 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"54893_CR63","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1038\/ncomms4283","volume":"5","author":"E Fossati","year":"2014","unstructured":"Fossati, E. et al. Reconstitution of a 10-gene pathway for synthesis of the plant alkaloid dihydrosanguinarine in Saccharomyces cerevisiae. Nat. Commun. 5, 3283 (2014).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54893-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54893-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54893-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:01:51Z","timestamp":1790481711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54893-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54893"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54893-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29671"}}